KRCA-0713 is an ALK inhibitor with anti-ALK activity. KRCA-0713 showed promising anti-ALK activity in enzyme and cell-based experiments. KRCA-0713 was shown to effectively inhibit ALK-driven tumor growth in H3122 xenograft model studies, similar to the effect of ceritinib[1].
Molecular Weight:
530.08
CAS Number:
[1884321-89-4]
Formula:
C26H32ClN5O3S
Target:
Anaplastic lymphoma kinase (ALK)
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted